Summary
The provided AI claims are about Prozac pricing, discount programs, and switching to generic for cost reduction, none of which are supported, contradicted, or addressed in the supplied FDA label excerpts (which only cover suicidality boxed warning/counseling and pediatric use). Therefore, label alignment cannot be established from the provided prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
Prozac prices without insurance depend on the strength and form used (capsules vs. liquid).
No pricing, pharmacy cost, formulation-related pricing, or insurance/cash price information is present in the supplied label excerpts.
Without insurance, patients usually pay the pharmacy's cash price for Prozac.
No information in the supplied label excerpts addresses how patients pay for Prozac without insurance.
Prozac cash prices vary widely from one store to another.
No pricing or store-to-store variability information is present in the supplied label excerpts.
A cash price estimate for Prozac is time-sensitive and location-specific.
No information in the supplied label excerpts addresses time/location variability of cash price estimates.
DrugPatentWatch.com tracks prescription-drug information and can be used to compare Prozac pricing context.
The supplied FDA label excerpts do not mention this website or any third-party pricing comparison tool.
Pharmacy discount programs may be available for Prozac even if a patient does not have insurance.
No information in the supplied label excerpts addresses discount programs or eligibility independent of insurance.
Manufacturer or patient assistance programs for Prozac availability depend on eligibility and current program rules.
The supplied label excerpts do not describe manufacturer/patient assistance programs or their eligibility/rules.
Switching from brand Prozac to the generic (fluoxetine) may reduce out-of-pocket cost because generics are typically much cheaper.
The supplied label excerpts do not discuss generic substitution for cost, relative pricing, or out-of-pocket cost reduction.
In many markets, generic fluoxetine is substantially cheaper than brand Prozac for the same dose and similar dosing schedule.
No pricing comparison or market-level cost information is present in the supplied label excerpts.
Asking the pharmacy for the cash price of generic fluoxetine and whether it is available in the exact dose is usually the quickest way to reduce spending when cost is the main concern.
The supplied label excerpts do not provide guidance on cost-saving strategies, cash price requests, or pharmacy availability inquiries.
Requesting a cash price should include the cash price for the exact strength and form.
The supplied label excerpts do not contain instructions about requesting cash prices by strength/form.
When requesting a cash price, asking whether substituting generic fluoxetine is allowed for the prescription is relevant.
The supplied label excerpts do not address substitution rules or whether generic substitution is allowed.
When requesting a cash price, asking for the total cost for the full quantity being filled (30-day vs. 90-day supply) is relevant.
The supplied label excerpts do not discuss quantity-based cash pricing comparisons.
When requesting a cash price, asking whether any discount card or in-store program applies even without insurance is relevant.
The supplied label excerpts do not discuss discount cards/in-store programs or cash pricing relevance.
A 90-day fill can reduce per-day cost versus a 30-day fill only if that pricing is lower at the pharmacy.
No label content regarding per-day cost, fill duration pricing, or pharmacy pricing comparisons is present.
Patients should ask for both 30-day and 90-day prices when comparing costs.
The supplied label excerpts do not provide counseling instructions about asking for pricing for different supply durations.
Contradictions
Important Omissions
No AI claim addresses the label’s specific boxed warning content (suicidal thoughts/behaviors in children, adolescents, and young adults), monitoring instructions, or age-approval limitations referenced in the supplied label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims concern pricing/assistance and generic switching for cost reduction and do not directly conflict with the supplied boxed warning/monitoring/pediatric-use information. However, the claims are not supported by the supplied label content, limiting on-label verification.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Provided claims are about pricing/assistance/substitution logistics and are not addressed or supported by the supplied FDA label excerpts.
Suggested Improvement
Restrict claims to sections present in the provided label excerpts (boxed warning/Section 5.1 monitoring; Section 17 counseling; pediatric use limitations). Remove or qualify pricing/cost/discount-program claims unless the relevant prescribing information is provided.